Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemothera
Authors
Chengqiang Li (ORCID: https://orcid.org/0000-0002-8549-2416)
Yuqin Cao (ORCID: https://orcid.org/0000-0003-0127-7557)
Liqin Zhao
Yingyi Li (ORCID: https://orcid.org/0000-0002-0895-6803)
Xipeng Wang (ORCID: https://orcid.org/0009-0002-6804-0829)
National Key Research and Development Program of China
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemothera
Chengqiang Li, Yuqin Cao, Liqin Zhao, Yingyi Li et al.
Citations
4 citations
Journal
BMC Cancer
Topics
Esophageal Cancer Research and Treatment
Field-Weighted Citation Impact (FWCI)
8.03
article
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemothera
Chengqiang Li, Yuqin Cao, Liqin Zhao, Yingyi Li, Xipeng Wang
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
Shanghai Jiao Tong University (CN), Ruijin Hospital (CN)
Funders
National Natural Science Foundation of China, National Key Research and Development Program of China